Maryzola (Memantine Hydrochloride)

Memantine works by binding to the NMDA‑type glutamate receptor channel as a non‑competitive antagonist. This blocks excessive calcium entry that occurs during prolonged glutamate stimulation, reducing excitotoxic neuronal damage while preserving normal synaptic transmission, which contributes to its therapeutic effect in Alzheimer’s disease.

The appropriate dose of Maryzola is determined by the prescribing healthcare professional based on the individual’s clinical condition, age, renal function and other factors. Physicians typically start with a low dose and may titrate upward, but the exact regimen should be followed as directed on the prescription label.

Safety data for memantine in pregnancy and lactation are limited. The product should be used only if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the risks and benefits with their healthcare provider.

To place an order, submit an enquiry on the Maryzola product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details and any required import documentation.

The primary alternative class for Alzheimer’s disease is acetylcholinesterase inhibitors such as donepezil. While both classes aim to improve cognition, memantine targets glutamatergic excitotoxicity, whereas acetylcholinesterase inhibitors enhance cholinergic transmission. Clinical practice often uses memantine alone for moderate‑to‑severe disease or in combination with an acetylcholinesterase inhibitor for broader symptom control.

Maryzola tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and heat. Keep the product out of reach of children and avoid exposure to direct sunlight. No special refrigeration is required.

Maryzola is administered orally as a tablet. Patients should swallow the tablet whole with water, with or without food, unless otherwise instructed by their prescriber. The dosage schedule, including any titration steps, must follow the prescribing information provided by the treating physician.

Serious adverse reactions, although uncommon, include seizures, cardiac arrhythmias and severe allergic responses such as anaphylaxis. Patients should seek immediate medical attention if they experience convulsions, irregular heartbeats, rash, swelling of the face or throat, or difficulty breathing while on therapy.

Maryzola should not be used by individuals with known hypersensitivity to memantine or any excipients in the tablet. It is also contraindicated in patients with severe renal impairment where dosing cannot be appropriately adjusted, and in those taking other NMDA‑receptor antagonists due to the risk of additive neurotoxicity.